Runben Biotechnology Co Stock

Runben Biotechnology Co Liabilities

The The Liabilities of Runben Biotechnology Co (603193.SS) as of Aug 12, 2026 is 138.88 M CNY. In the previous year, The Liabilities was 97.61 M CNY — a change of 42.28% (higher).

Liabilities

138.88 MCNY

YoY

42.28%

Last updated:

In 2026, Runben Biotechnology Co's total liabilities amounted to 138.88 M CNY, a 42.28% difference from the 97.61 M CNY total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Runben Biotechnology Co's Liabilities

Runben Biotechnology Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Runben Biotechnology Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Runben Biotechnology Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Runben Biotechnology Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Runben Biotechnology Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Runben Biotechnology Co stock

The Liabilities of Runben Biotechnology Co is 138.88 M CNY in 2026.

The Liabilities of Runben Biotechnology Co changed from 97.61 M CNY to 138.88 M CNY, representing a 42.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Runben Biotechnology Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Runben Biotechnology Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Runben Biotechnology Co